Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE A GARCIA ZUAZAGA

Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery

NPI
1407979529
CMS profile
830298
Location
CONCORD TOWNSHIP, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$24,381.63

42 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE A GARCIA ZUAZAGA

NPI 1407979529 · CMS profile ID 830298

Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery

CONCORD TOWNSHIP, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407979529?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407979529?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407979529?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1407979529?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

42 matching records · $24,381.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 42 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–42 of 42.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $19.5512/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918106197 CMS
Lilly USA, LLC $14.3812/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918125305 CMS
Regeneron Healthcare Solutions, Inc. $22.4912/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927173039 CMS
ABBVIE INC. $5.5312/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891006021 CMS
ABBVIE INC. $14.8911/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891006019 CMS
ABBVIE INC. $22.7011/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891006017 CMS
GENZYME CORPORATION $33.2611/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938885243 CMS
Lilly USA, LLC $16.4311/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918145527 CMS
GENZYME CORPORATION $2.6510/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938885239 CMS
Janssen Scientific Affairs, LLC $125.0010/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887249823 CMS
Regeneron Healthcare Solutions, Inc. $16.7410/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927173035 CMS
ABBVIE INC. $5.7910/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891006015 CMS
ABBVIE INC. $13.7310/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891006013 CMS
Lilly USA, LLC $23.4810/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918106195 CMS
UCB, Inc. $14.7610/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965217299 CMS
Regeneron Healthcare Solutions, Inc. $803.6610/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927173031 CMS
GENZYME CORPORATION $21.8809/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938885231 CMS
Lilly USA, LLC $17.9409/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918096769 CMS
ABBVIE INC. $17.6709/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891006011 CMS
Lilly USA, LLC $19.2408/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918167703 CMS
Incyte Corporation $20.6008/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943057051 CMS
ABBVIE INC. $15.1707/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891006009 CMS
Sun Pharmaceutical Industries Inc. $21.2607/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947805507 CMS
GENZYME CORPORATION $24.9906/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938885207 CMS
GENZYME CORPORATION $125.0006/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938885211 CMS
GENZYME CORPORATION $2,951.0006/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938885213 CMS
Nabriva Therapeutics, plc $16.4905/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 961086527 CMS
Incyte Corporation $19.7605/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943056961 CMS
ABBVIE INC. $19.5105/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891006007 CMS
ABBVIE INC. $18.4405/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891006005 CMS
Janssen Biotech, Inc. $20.7804/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886380015 CMS
Nabriva Therapeutics, plc $11.9104/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 961086525 CMS
Sun Pharmaceutical Industries Inc. $23.2104/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947805503 CMS
ABBVIE INC. $18.3104/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891006003 CMS
GENZYME CORPORATION $23.8903/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938885197 CMS
Janssen Scientific Affairs, LLC $62.1703/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887249817 CMS
Ethicon Inc. $11,110.0003/17/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887033129 CMS
Ethicon Inc. $6,060.0003/14/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887033135 CMS
EPI Health, LLC $17.3002/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960432637 CMS
Regeneron Healthcare Solutions, Inc. $2,529.0002/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927173027 CMS
Genentech USA, Inc. $17.5401/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950804445 CMS
Regeneron Healthcare Solutions, Inc. $23.5301/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927173023 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,268.57 21
PY2020 $1,238.59 7
PY2021 $12,408.53 45
PY2022 $24,381.63 42
PY2023 $84,667.07 52
PY2024 $16,980.08 79
PY2025 $2,421.43 52

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,893,327.58 407
PY2024 Principal investigator $2,667,688.93 422
PY2023 Recipient $18,196.50 3
PY2023 Principal investigator $882,864.23 139
PY2022 Principal investigator $164,380.88 32
PY2021 Recipient $18,912.00 5
PY2021 Principal investigator $12,300.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

422 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $9,550.36 12/30/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100763354
Principal investigator 1 Janssen Research & Development, LLC $218.00 12/30/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975755
Principal investigator 1 Janssen Research & Development, LLC $218.00 12/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975583
Principal investigator 1 Janssen Research & Development, LLC $824.00 12/24/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975883
Principal investigator 1 PFIZER INC. $10,800.00 12/20/2024 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1130964444
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,970.26 12/20/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 1125501262
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 12/19/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975523
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 12/19/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975565
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 12/19/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975571
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 12/19/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975621
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 12/19/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975625
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 12/19/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975749
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 12/19/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975783
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 12/19/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975863
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 12/19/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975927
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 12/19/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975939
Principal investigator 1 Janssen Research & Development, LLC $4,234.40 12/19/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975969
Principal investigator 1 Janssen Research & Development, LLC $455.00 12/18/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975501
Principal investigator 1 Janssen Research & Development, LLC $455.00 12/18/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975503
Principal investigator 1 Janssen Research & Development, LLC $218.00 12/18/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975521
Principal investigator 1 Janssen Research & Development, LLC $250.00 12/18/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975549
Principal investigator 1 Janssen Research & Development, LLC $824.00 12/18/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975555
Principal investigator 1 Janssen Research & Development, LLC $50.00 12/18/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975581
Principal investigator 1 Janssen Research & Development, LLC $218.00 12/18/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975593
Principal investigator 1 Janssen Research & Development, LLC $50.00 12/18/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975675
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $55.00 12/18/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 1125501108
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,950.00 12/18/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125501110
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 12/18/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 1125501112
Principal investigator 1 ABBVIE INC. $18,744.22 12/17/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100761523
Principal investigator 1 SANOFI US SERVICES INC. $1,200.00 12/16/2024 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1128719821
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 12/11/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125500438
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,176.65 12/11/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125500448
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23,989.92 12/11/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125500496
Principal investigator 1 ABBVIE INC. $5,288.82 12/05/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100759411
Principal investigator 1 ABBVIE INC. $750.00 12/05/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1100759489
Principal investigator 1 PFIZER INC. $2,859.58 12/05/2024 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1130964450
Principal investigator 1 ABBVIE INC. $1,715.16 12/04/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 1100758115
Principal investigator 1 ABBVIE INC. $4,363.04 12/04/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1100758117
Principal investigator 1 Janssen Research & Development, LLC $201.00 12/04/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975637
Principal investigator 1 Janssen Research & Development, LLC $254.00 12/04/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975923
Principal investigator 1 Janssen Research & Development, LLC $200.00 12/04/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975951
Principal investigator 1 ABBVIE INC. $966.00 12/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100757559
Principal investigator 1 SANOFI US SERVICES INC. $9,974.96 12/03/2024 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1128719823
Principal investigator 1 SANOFI US SERVICES INC. $50.00 12/03/2024 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1128719825
Principal investigator 1 SANOFI US SERVICES INC. $100.00 12/03/2024 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1128719827
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 12/02/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975699
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 12/02/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975727
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975513
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975517
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975527
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975573
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975575
Principal investigator 1 Janssen Research & Development, LLC $3,537.60 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975607
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975653
Principal investigator 1 Janssen Research & Development, LLC $3,537.60 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975655
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975667
Principal investigator 1 Janssen Research & Development, LLC $3,537.60 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975735
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975789
Principal investigator 1 Janssen Research & Development, LLC $3,537.60 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975823
Principal investigator 1 Janssen Research & Development, LLC $4,234.40 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975871
Principal investigator 1 Janssen Research & Development, LLC $3,537.60 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975893
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975909
Principal investigator 1 Janssen Research & Development, LLC $3,537.60 11/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975973
Principal investigator 1 PFIZER INC. $1,850.54 11/26/2024 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1130987255
Principal investigator 1 Janssen Research & Development, LLC $5,184.00 11/22/2024 Non-covered Recipient Entity
Apex Derm Mayfield Hts
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975801
Principal investigator 1 Incyte Corporation $1,200.00 11/21/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1134679041
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.50 11/20/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125499626
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $925.00 11/20/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125499628
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 11/20/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125499630
Principal investigator 1 Janssen Research & Development, LLC $2,363.00 11/15/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975553
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 11/15/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975725
Principal investigator 1 Janssen Research & Development, LLC $2,363.00 11/15/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975845
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 11/15/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975849
Principal investigator 1 Janssen Research & Development, LLC $250.00 11/15/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975855
Principal investigator 1 Incyte Corporation $265.32 11/14/2024 Non-covered Recipient Entity
APEX DERMATOLOGY
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134679059
Principal investigator 1 ABBVIE INC. $12,073.58 11/07/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100753309
Principal investigator 1 ABBVIE INC. $1,779.02 11/07/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100753311
Principal investigator 1 PFIZER INC. $2,196.26 11/05/2024 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1130987141
Principal investigator 1 Janssen Research & Development, LLC $4,234.40 11/04/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975515
Principal investigator 1 SANOFI US SERVICES INC. $10,000.00 11/01/2024 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1128719829
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50,281.88 11/01/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125499041
Principal investigator 1 ABBVIE INC. $59.34 10/30/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100750830
Principal investigator 1 Janssen Research & Development, LLC $150.00 10/30/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975787
Principal investigator 1 Incyte Corporation $1,530.00 10/24/2024 Non-covered Recipient Entity
APEX DERMATOLOGY
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134679057
Principal investigator 1 PFIZER INC. $2,730.54 10/24/2024 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1130994915
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $27,910.00 10/16/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 1125498555
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 10/16/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 1125498557
Principal investigator 1 Janssen Research & Development, LLC $3,670.00 10/07/2024 Non-covered Recipient Entity
Apex Derm Mayfield Hts
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975807
Principal investigator 1 PFIZER INC. $6,511.96 10/05/2024 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1130994909
Principal investigator 1 ABBVIE INC. $1,755.40 10/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1100745680
Principal investigator 1 ABBVIE INC. $17,362.40 10/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100745702
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 10/03/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975525
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 10/03/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975695
Principal investigator 1 SANOFI US SERVICES INC. $34,000.00 10/02/2024 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1128719813
Principal investigator 1 ABBVIE INC. $16,400.00 10/01/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100744958
Principal investigator 1 Incyte Corporation $3,588.00 09/26/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1134679039
Principal investigator 1 Janssen Research & Development, LLC $50.00 09/26/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975949
Principal investigator 1 Janssen Research & Development, LLC $1,648.00 09/26/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975967
Principal investigator 1 PFIZER INC. $7,817.38 09/25/2024 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131019734
Principal investigator 1 Janssen Research & Development, LLC $3,443.80 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975519
Principal investigator 1 Janssen Research & Development, LLC $3,537.60 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975599
Principal investigator 1 Janssen Research & Development, LLC $3,443.80 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975613
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975617
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975623
Principal investigator 1 Janssen Research & Development, LLC $3,443.80 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975643
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975661
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975663
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975679
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975701
Principal investigator 1 Janssen Research & Development, LLC $3,537.60 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975703
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975709
Principal investigator 1 Janssen Research & Development, LLC $3,537.60 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975743
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975745
Principal investigator 1 Janssen Research & Development, LLC $3,443.80 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975753
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975785
Principal investigator 1 Janssen Research & Development, LLC $3,443.80 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975821
Principal investigator 1 Janssen Research & Development, LLC $4,234.40 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975853
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975859
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975865
Principal investigator 1 Janssen Research & Development, LLC $4,234.40 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975877
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975881
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975901
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975921
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975933
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975943
Principal investigator 1 Janssen Research & Development, LLC $3,443.80 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975945
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 09/20/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975953
Principal investigator 1 Janssen Research & Development, LLC $218.00 09/18/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975717
Principal investigator 1 Janssen Research & Development, LLC $218.00 09/18/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975775
Principal investigator 1 Janssen Research & Development, LLC $218.00 09/18/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975835
Principal investigator 1 ABBVIE INC. $1,340.00 09/11/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1100741854
Principal investigator 1 ABBVIE INC. $8,000.00 09/11/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1100741856
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $56,428.71 09/11/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125497147
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,950.00 09/11/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125497149
Principal investigator 1 SANOFI US SERVICES INC. $32,000.00 09/09/2024 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128719811
Principal investigator 1 Janssen Research & Development, LLC $50.00 09/06/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975739
Principal investigator 1 Janssen Research & Development, LLC $400.00 09/06/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975757
Principal investigator 1 ABBVIE INC. $22,117.22 09/04/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100740088
Principal investigator 1 PFIZER INC. $5,653.48 09/04/2024 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131019050
Principal investigator 1 ABBVIE INC. $1,888.02 09/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 1100738888
Principal investigator 1 ABBVIE INC. $1,755.40 09/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1100738890
Principal investigator 1 ABBVIE INC. $44.22 09/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100738896
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 09/02/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975563
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 09/02/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975769
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $38,275.50 08/30/2024 Non-covered Recipient Entity
Apex Clinical Research Center Llc
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis No dispute reported 06/30/2026 1123475902
Principal investigator 1 Janssen Research & Development, LLC $4,360.00 08/30/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975947
Principal investigator 1 Incyte Corporation $5,000.00 08/29/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1134679029
Principal investigator 1 Incyte Corporation $2,500.00 08/29/2024 Non-covered Recipient Entity
APEX DERMATOLOGY
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134679061
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 08/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975721
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 08/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975861
Principal investigator 1 Eli Lilly and Company $69,711.21 08/16/2024 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS OF MARYLAND PA
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1137353844
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,250.00 08/16/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125495805
Principal investigator 1 Dermavant Sciences, Inc. $14.74 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896545
Principal investigator 1 Dermavant Sciences, Inc. $14.74 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896549
Principal investigator 1 Dermavant Sciences, Inc. $61.01 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896554
Principal investigator 1 Dermavant Sciences, Inc. $61.01 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896558
Principal investigator 1 Dermavant Sciences, Inc. $84.80 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896562
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896567
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896571
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896575
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896584
Principal investigator 1 Dermavant Sciences, Inc. $84.80 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896588
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896592
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896596
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896601
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896605
Principal investigator 1 Dermavant Sciences, Inc. $84.80 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896609
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896613
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896617
Principal investigator 1 Dermavant Sciences, Inc. $14.74 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127921991
Principal investigator 1 Dermavant Sciences, Inc. $14.74 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127921995
Principal investigator 1 Dermavant Sciences, Inc. $61.01 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127921999
Principal investigator 1 Dermavant Sciences, Inc. $61.01 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922003
Principal investigator 1 Dermavant Sciences, Inc. $84.80 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922008
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922012
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922016
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922020
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922029
Principal investigator 1 Dermavant Sciences, Inc. $84.80 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922033
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922038
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922042
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922047
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922051
Principal investigator 1 Dermavant Sciences, Inc. $84.80 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922055
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922059
Principal investigator 1 Dermavant Sciences, Inc. $63.42 08/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922063
Principal investigator 1 ABBVIE INC. $13,836.52 08/02/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100734240
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $107.20 08/01/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125494727
Principal investigator 1 ABBVIE INC. $44.22 07/30/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100731286
Principal investigator 1 Janssen Research & Development, LLC $3,443.80 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975537
Principal investigator 1 Janssen Research & Development, LLC $3,725.20 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975569
Principal investigator 1 Janssen Research & Development, LLC $3,537.60 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975577
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975589
Principal investigator 1 Janssen Research & Development, LLC $3,725.20 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975601
Principal investigator 1 Janssen Research & Development, LLC $3,725.20 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975649
Principal investigator 1 Janssen Research & Development, LLC $3,725.20 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975693
Principal investigator 1 Janssen Research & Development, LLC $3,443.80 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975715
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975731
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975737
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975805
Principal investigator 1 Janssen Research & Development, LLC $3,443.80 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975809
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975833
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975851
Principal investigator 1 Janssen Research & Development, LLC $3,725.20 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975879
Principal investigator 1 Janssen Research & Development, LLC $3,537.60 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975929
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 07/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975977
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126,921.42 07/24/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125494337
Principal investigator 1 Dermavant Sciences, Inc. $63.42 07/23/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879391
Principal investigator 1 Janssen Research & Development, LLC $191.00 07/22/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975567
Principal investigator 1 Incyte Corporation $7,500.00 07/18/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1134679037
Principal investigator 1 Janssen Research & Development, LLC $824.00 07/17/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975799
Principal investigator 1 Incyte Corporation $5,138.00 07/11/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1134679017
Principal investigator 1 Incyte Corporation $828.00 07/11/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1134679035
Principal investigator 1 ABBVIE INC. $4,036.08 07/05/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1100727382
Principal investigator 1 ABBVIE INC. $31,875.78 07/05/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100727384
Principal investigator 1 ABBVIE INC. $1,888.02 07/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 1100725858
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,872.00 07/03/2024 Non-covered Recipient Entity
Western University Review Board (wirb)
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis No dispute reported 06/30/2026 1123481723
Principal investigator 1 Janssen Research & Development, LLC $100.00 07/01/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975915
Principal investigator 1 Janssen Research & Development, LLC $2,580.00 07/01/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975937
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975547
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975559
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975603
Principal investigator 1 Janssen Research & Development, LLC $3,725.20 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975605
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975651
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975683
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975685
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975689
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975765
Principal investigator 1 Janssen Research & Development, LLC $2,363.00 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975779
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975781
Principal investigator 1 Janssen Research & Development, LLC $3,537.60 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975887
Principal investigator 1 Janssen Research & Development, LLC $3,537.60 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975981
Principal investigator 1 Janssen Research & Development, LLC $50.00 06/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975985
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 06/26/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975645
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 06/26/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975811
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,950.00 06/26/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125492980
Principal investigator 1 ABBVIE INC. $1,500.00 06/20/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100724180
Principal investigator 1 Dermavant Sciences, Inc. $2,000.00 06/15/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877913
Principal investigator 1 Dermavant Sciences, Inc. $2,000.00 06/15/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877917
Principal investigator 1 Dermavant Sciences, Inc. $160.80 06/15/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877921
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 06/15/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877925
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 06/15/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877930
Principal investigator 1 Dermavant Sciences, Inc. $1,200.00 06/15/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877934
Principal investigator 1 Dermavant Sciences, Inc. $1,200.00 06/15/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877938
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 06/15/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877946
Principal investigator 1 Dermavant Sciences, Inc. $500.00 06/15/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877951
Principal investigator 1 ABBVIE INC. $8,000.00 06/13/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100723524
Principal investigator 1 ABBVIE INC. $21,285.96 06/06/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100722566
Principal investigator 1 Janssen Research & Development, LLC $50.00 06/05/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975819
Principal investigator 1 Janssen Research & Development, LLC $1,943.00 06/05/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975841
Principal investigator 1 ABBVIE INC. $420.00 06/03/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100720376
Principal investigator 1 Incyte Corporation $8,812.00 05/30/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1134679027
Principal investigator 1 Incyte Corporation $92.00 05/30/2024 Non-covered Recipient Entity
APEX DERMATOLOGY
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134679053
Principal investigator 1 Incyte Corporation $1,853.00 05/30/2024 Non-covered Recipient Entity
APEX DERMATOLOGY
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134679055
Principal investigator 1 Janssen Research & Development, LLC $824.00 05/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975597
Principal investigator 1 Janssen Research & Development, LLC $824.00 05/29/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975899
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975499
Principal investigator 1 Janssen Research & Development, LLC $3,256.20 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975509
Principal investigator 1 Janssen Research & Development, LLC $3,725.20 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975533
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975535
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975543
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975551
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975557
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975659
Principal investigator 1 Janssen Research & Development, LLC $3,443.80 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975691
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975707
Principal investigator 1 Janssen Research & Development, LLC $3,725.20 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975711
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975713
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975741
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975747
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975795
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975803
Principal investigator 1 Janssen Research & Development, LLC $3,443.80 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975829
Principal investigator 1 Janssen Research & Development, LLC $3,443.80 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975885
Principal investigator 1 Janssen Research & Development, LLC $1,878.68 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975891
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975935
Principal investigator 1 Janssen Research & Development, LLC $3,443.80 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975959
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975971
Principal investigator 1 Janssen Research & Development, LLC $3,725.20 05/27/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975987
Principal investigator 1 Eli Lilly and Company $938.00 05/20/2024 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS OF MARYLAND PA
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1137353236
Principal investigator 1 ABBVIE INC. $4,825.00 05/16/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1100718642
Principal investigator 1 Incyte Corporation $1,071.00 05/16/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1134679047
Principal investigator 1 Janssen Research & Development, LLC $4,287.00 05/10/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975991
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $41,258.62 05/10/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125491018
Principal investigator 1 Incyte Corporation $8,000.00 05/09/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1134679033
Principal investigator 1 ABBVIE INC. $1,755.40 05/08/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1100715956
Principal investigator 1 Amgen Inc. $1,523.67 04/25/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
OUTPOST Clinical Home Use Study No dispute reported 06/30/2026 1096311895
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,950.00 04/24/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125490241
Principal investigator 1 Amgen Inc. $94,712.62 04/20/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309031
Principal investigator 1 Amgen Inc. $43,010.00 04/20/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
ASTRO P3 AD Adolescent Mono No dispute reported 06/30/2026 1096309603
Principal investigator 1 Amgen Inc. $205,383.76 04/20/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
OUTPOST Clinical Home Use Study No dispute reported 06/30/2026 1096311897
Principal investigator 1 Amgen Inc. $81,898.40 04/20/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
VOYAGER P3 AD Vaccine Study No dispute reported 06/30/2026 1096316356
Principal investigator 1 Janssen Research & Development, LLC $350.00 04/19/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975507
Principal investigator 1 Janssen Research & Development, LLC $3,994.00 04/19/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975595
Principal investigator 1 Janssen Research & Development, LLC $500.00 04/17/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975771
Principal investigator 1 Janssen Research & Development, LLC $156.00 04/17/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975791
Principal investigator 1 Janssen Research & Development, LLC $574.00 04/17/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975839
Principal investigator 1 Janssen Research & Development, LLC $201.00 04/17/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975867
Principal investigator 1 Janssen Research & Development, LLC $254.00 04/17/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975919
Principal investigator 1 Janssen Research & Development, LLC $574.00 04/17/2024 Non-covered Recipient Entity
Apex Clinic Rsrch Ctr Llc
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975955
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,949.65 04/17/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125489825
Principal investigator 1 Incyte Corporation $3,384.84 04/10/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1134679031
Principal investigator 1 PFIZER INC. $2,500.00 04/05/2024 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131086071
Principal investigator 1 ABBVIE INC. $1,755.40 04/04/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1100710964
Principal investigator 1 ABBVIE INC. $463.64 04/04/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 1100710988
Principal investigator 1 ABBVIE INC. $11,553.24 04/04/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 1100711038
Principal investigator 1 ABBVIE INC. $37,127.84 04/04/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 1100711040
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $133,518.90 04/04/2024 Non-covered Recipient Entity
Apex Clinical Research Center
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1123475898
Principal investigator 1 Incyte Corporation $1,880.00 04/04/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1134679025
Principal investigator 1 Incyte Corporation $2,325.00 03/28/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1134679023
Principal investigator 1 Janssen Research & Development, LLC $2,657.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975545
Principal investigator 1 Janssen Research & Development, LLC $3,597.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975629
Principal investigator 1 Janssen Research & Development, LLC $3,597.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975631
Principal investigator 1 Janssen Research & Development, LLC $3,597.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975639
Principal investigator 1 Janssen Research & Development, LLC $5,314.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975673
Principal investigator 1 Janssen Research & Development, LLC $3,597.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975677
Principal investigator 1 Janssen Research & Development, LLC $2,657.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975723
Principal investigator 1 Janssen Research & Development, LLC $2,657.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975751
Principal investigator 1 Janssen Research & Development, LLC $2,657.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975761
Principal investigator 1 Janssen Research & Development, LLC $3,597.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975813
Principal investigator 1 Janssen Research & Development, LLC $3,597.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975843
Principal investigator 1 Janssen Research & Development, LLC $3,597.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975913
Principal investigator 1 Janssen Research & Development, LLC $3,597.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975961
Principal investigator 1 Janssen Research & Development, LLC $2,657.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975979
Principal investigator 1 Janssen Research & Development, LLC $2,657.00 03/28/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975989
Principal investigator 1 Janssen Research & Development, LLC $3,256.20 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975529
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975561
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975633
Principal investigator 1 Janssen Research & Development, LLC $4,247.80 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975669
Principal investigator 1 Janssen Research & Development, LLC $3,256.20 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975681
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975705
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975729
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975767
Principal investigator 1 Janssen Research & Development, LLC $3,725.20 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975777
Principal investigator 1 Janssen Research & Development, LLC $3,725.20 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975895
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975903
Principal investigator 1 Janssen Research & Development, LLC $3,256.20 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975917
Principal investigator 1 Janssen Research & Development, LLC $3,256.20 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975931
Principal investigator 1 Janssen Research & Development, LLC $3,256.20 03/27/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975957
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $35,037.67 03/27/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125488913
Principal investigator 1 Amgen Inc. $14,339.23 03/26/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
OUTPOST Clinical Home Use Study No dispute reported 06/30/2026 1096311899
Principal investigator 1 Janssen Research & Development, LLC $433.00 03/25/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975647
Principal investigator 1 Janssen Research & Development, LLC $8,044.00 03/25/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975773
Principal investigator 1 Janssen Research & Development, LLC $9,008.00 03/25/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975869
Principal investigator 1 Janssen Research & Development, LLC $254.00 03/25/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975965
Principal investigator 1 Janssen Research & Development, LLC $824.00 03/22/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975983
Principal investigator 1 Incyte Corporation $1,880.00 03/21/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1134679015
Principal investigator 1 Janssen Research & Development, LLC $4,247.80 03/21/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975539
Principal investigator 1 Janssen Research & Development, LLC $3,256.20 03/21/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975591
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 03/21/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975619
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 03/21/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975635
Principal investigator 1 Janssen Research & Development, LLC $4,247.80 03/21/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975641
Principal investigator 1 Janssen Research & Development, LLC $4,247.80 03/21/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975665
Principal investigator 1 Janssen Research & Development, LLC $4,247.80 03/21/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975671
Principal investigator 1 Janssen Research & Development, LLC $4,247.80 03/21/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975905
Principal investigator 1 Janssen Research & Development, LLC $7,054.00 03/20/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975585
Principal investigator 1 Janssen Research & Development, LLC $574.00 03/20/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975759
Principal investigator 1 Janssen Research & Development, LLC $574.00 03/20/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975825
Principal investigator 1 Janssen Research & Development, LLC $156.00 03/20/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975897
Principal investigator 1 Janssen Research & Development, LLC $574.00 03/20/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975911
Principal investigator 1 Janssen Research & Development, LLC $300.00 03/20/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975993
Principal investigator 1 Janssen Research & Development, LLC $156.00 03/20/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975995
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $975.00 03/20/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125488341
Principal investigator 1 Janssen Research & Development, LLC $2,263.00 03/18/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975889
Principal investigator 1 Janssen Research & Development, LLC $824.00 03/15/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975511
Principal investigator 1 PFIZER INC. $18,000.00 03/15/2024 Non-covered Recipient Entity
Apex Clinical Research Center LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131100667
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 03/15/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125488089
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,845.70 03/07/2024 Non-covered Recipient Entity
Apex Clinical Research
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1155196459
Principal investigator 1 Incyte Corporation $725.00 03/07/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1134679043
Principal investigator 1 Incyte Corporation $3,870.00 03/07/2024 Non-covered Recipient Entity
APEX DERMATOLOGY
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134679051
Principal investigator 1 Incyte Corporation $21,130.66 03/06/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1134679045
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 02/29/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975531
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 02/29/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975579
Principal investigator 1 Janssen Research & Development, LLC $3,256.20 02/29/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975587
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 02/29/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975627
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 02/29/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975797
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 02/29/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975817
Principal investigator 1 Janssen Research & Development, LLC $3,725.20 02/29/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975837
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 02/29/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975847
Principal investigator 1 Janssen Research & Development, LLC $3,725.20 02/29/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975857
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 02/29/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975873
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,039.89 02/28/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125487082
Principal investigator 1 Amgen Inc. $1,719.77 02/26/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
ASTRO P3 AD Adolescent Mono No dispute reported 06/30/2026 1096309601
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 02/26/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975505
Principal investigator 1 Janssen Research & Development, LLC $4,327.00 02/26/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975657
Principal investigator 1 Janssen Research & Development, LLC $4,247.80 02/26/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975687
Principal investigator 1 Janssen Research & Development, LLC $3,256.20 02/26/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975763
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 02/23/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125486908
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 02/23/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125486910
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $120,769.86 02/21/2024 Non-covered Recipient Entity
Apex Clinical Research Center
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1123475900
Principal investigator 1 Incyte Corporation $10,791.00 02/15/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1134679021
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,981.28 02/09/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125486141
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 02/08/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975541
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 02/08/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975609
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 02/08/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975793
Principal investigator 1 Janssen Research & Development, LLC $4,247.80 02/08/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975815
Principal investigator 1 Janssen Research & Development, LLC $2,854.20 02/08/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975831
Principal investigator 1 Janssen Research & Development, LLC $4,247.80 02/08/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975875
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 02/08/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975941
Principal investigator 1 ABBVIE INC. $2,018.04 02/01/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1100702288
Principal investigator 1 Incyte Corporation $39,563.76 02/01/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1134679049
Principal investigator 1 Amgen Inc. $26,376.38 01/25/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309033
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,656.70 01/25/2024 Non-covered Recipient Entity
Apex Clinical Research
A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUTING IMPACT OF DEUCRAVACITINIB ON QoL, EFFICACY AND SAFETY IN PATIENTS WITH PLAQUE PSORIASIS AND IMPAIRED HEALTH-RELATED QUALITY OF LIFE No dispute reported 06/30/2026 1123475896
Principal investigator 1 Janssen Research & Development, LLC $191.00 01/25/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975615
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 01/25/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975719
Principal investigator 1 Janssen Research & Development, LLC $3,256.20 01/25/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975827
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $63,592.20 01/18/2024 Non-covered Recipient Entity
Apex Clinical Research
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1155196457
Principal investigator 1 Amgen Inc. $7,905.28 01/11/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
ASTRO P3 AD Adolescent Mono No dispute reported 06/30/2026 1096309605
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,949.65 01/10/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125483489
Principal investigator 1 Janssen Research & Development, LLC $4,247.80 01/08/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975611
Principal investigator 1 Janssen Research & Development, LLC $3,256.20 01/08/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975697
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 01/08/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975907
Principal investigator 1 Janssen Research & Development, LLC $4,247.80 01/08/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975925
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 01/08/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975963
Principal investigator 1 Janssen Research & Development, LLC $3,095.40 01/08/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 1078975975
Principal investigator 1 Janssen Research & Development, LLC $2,698.00 01/05/2024 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 1078975733
Principal investigator 1 ABBVIE INC. $2,036.80 01/04/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1100697985
Principal investigator 1 Incyte Corporation $2,317.00 01/04/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1134679019
Principal investigator 1 PFIZER INC. $2,495.00 01/03/2024 Non-covered Recipient Entity
Apex Clinical Research Center
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131019728
Principal investigator 1 SANOFI US SERVICES INC. $15,000.00 01/03/2024 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1128719783
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 01/03/2024 Non-covered Recipient Entity
Apex Clinical Research Center Llc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1128719785
Principal investigator 1 Amgen Inc. $10,529.77 01/02/2024 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
VOYAGER P3 AD Vaccine Study No dispute reported 06/30/2026 1096316358